A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech

Gene-therapy leader Sangamo Therapeutics has filed for Chapter 11 bankruptcy due to running out of cash, leaving its groundbreaking science in jeopardy. Key players like Eli Lilly and Astellas are now vying for the technology Sangamo has developed over decades. This move could reshape the landscape of gene therapy, with significant implications for future treatments and research funding. The bankruptcy highlights the financial strains faced by biotech firms, especially those investing heavily in cutting-edge but risky innovation.